Baclofen and Gamma-Hydroxybutyrate Withdrawal
- 265 Downloads
Benzodiazepine treatment of life-threatening gamma-hydroxybutyrate (GHB) withdrawal is frequently unsatisfactory. Animal studies suggest strongly that treatment with GABAB agonists, such as baclofen, will be a more effective strategy.
A case report from the medical intensive care unit (ICU) of the university tertiary care hospital.
A 61-year-old woman was admitted to the medical ICU for severe withdrawal symptoms from chronic GHB use. This manifested as delirium, tremor, and seizures despite only small decreases in GHB dose and treatment with benzodiazepines. The addition of baclofen allowed the rapid sequential decreases in the GHB dose without seizure or delirium and resulted in long-term improvement of her tremor.
Baclofen, a GABAB agonist, may be a useful agent in the treatment of severe GHB withdrawal.
KeywordsGamma-hydroxybutyrate dependence Baclofen Intention tremor
List of Abbreviations
Intensive care unit
- 5.A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1(4):391–7.Google Scholar
- 7.UCB and Jazz Pharmaceuticals Announce Expansion of Xyrem License to Include Fibromyalgia Syndrome (2006). http://www.jazzpharma.com/news.php?id=32.
- 8.Addolorato G, Castelli E, Stefanini GF, Casella G, Caputo F, Marsigli L, Bernardi M, Gasbarrini G. An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group. Alcohol Alcohol 1996;31(4):341–5.PubMedGoogle Scholar
- 12.Project GHB (2002). http://www.projectghb.org/addiction/addiction.htm.
- 16.Wu Y, Ali S, Ahmadian G, Liu CC, Wang YT, Gibson KM, Calver AR, Francis J, Pangalos MN, Carter Snead O III. Gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence. Neuropharmacology 2004;47(8):1146–56.PubMedCrossRefGoogle Scholar
- 22.Kaupmann K, Cryan JF, Wellendorph P, Mombereau C, Sansig G, Klebs K, Schmutz M, Froestl W, van der Putten H, Mosbacher J, et al. Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice. Eur J Neurosci 2003;18(10):2722–30.PubMedCrossRefGoogle Scholar